LitCoin-sentences  

PubMed:15630069 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-177 Sentence denotes Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
T2 178-189 Sentence denotes BACKGROUND:
T3 190-480 Sentence denotes While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
T4 481-491 Sentence denotes OBJECTIVE:
T5 492-642 Sentence denotes To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.
T6 643-650 Sentence denotes DESIGN:
T7 651-834 Sentence denotes A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
T8 835-843 Sentence denotes SETTING:
T9 844-968 Sentence denotes Subjects were recruited from an urban community mental health clinic and were studied at a general clinical research center.
T10 969-1092 Sentence denotes Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test.
T11 1093-1290 Sentence denotes Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
T12 1291-1313 Sentence denotes MAIN OUTCOME MEASURES:
T13 1314-1476 Sentence denotes Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
T14 1477-1485 Sentence denotes RESULTS:
T15 1486-1678 Sentence denotes The mean +/- SD duration of treatment with the identified atypical antipsychotic agent was 68.3 +/- 28.9 months (clozapine), 29.5 +/- 17.5 months (olanzapine), and 40.9 +/- 33.7 (risperidone).
T16 1679-1940 Sentence denotes Fasting serum insulin concentrations differed among groups (F(33) = 3.35; P = .047) (clozapine>olanzapine>risperidone) with significant differences between clozapine and risperidone (t(33) = 2.32; P = .03) and olanzapine and risperidone (t(33) = 2.15; P = .04).
T17 1941-2340 Sentence denotes There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
T18 2341-2597 Sentence denotes The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
T19 2598-2874 Sentence denotes There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).
T20 2875-2887 Sentence denotes CONCLUSIONS:
T21 2888-3067 Sentence denotes Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
T22 3068-3170 Sentence denotes Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.